Back to Search
Start Over
Efficacy and safety of nebivolol in Korean patients with hypertension by age and sex: a subanalysis from the BENEFIT-KOREA study
- Source :
- Clinical Hypertension, Vol 27, Iss 1, Pp 1-9 (2021)
- Publication Year :
- 2021
- Publisher :
- BMC, 2021.
-
Abstract
- Abstract Background BENEFIT-KOREA (BEnefits after 24 weeks of NEbivolol administration For essential hypertensIon patients wiTh various comorbidities and treatment environments in Korea) study, an observational study in South Korea, demonstrated the efficacy and safety of nebivolol in Asian patients with essential hypertension with and without comorbidities in real-world settings. We present a subanalysis of the efficacy and safety of nebivolol across age and sex in the BENEFIT-KOREA cohort. Methods Adult South Korean patients with essential hypertension participated in the prospective, single-arm, open, observational BENEFIT-KOREA study; 3011 patients received nebivolol as monotherapy or add-on therapy. Changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP), and pulse rate at 12 and 24 weeks were evaluated. Participants were divided into three age groups—young males and females:
Details
- Language :
- English
- ISSN :
- 20565909
- Volume :
- 27
- Issue :
- 1
- Database :
- Directory of Open Access Journals
- Journal :
- Clinical Hypertension
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.8d9805bbf33843a9af81a9bc0ad84682
- Document Type :
- article
- Full Text :
- https://doi.org/10.1186/s40885-021-00165-3